Keywords: Fragment screening; Surface plasmon resonance; Focal adhesion kinase; X-ray structure; DFG-out;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design
Keywords: DFG-in; Asp-Phe-Gly-in; DFG-out; Asp-Phe-Gly-out; GAFF; general AMBER force field; HF; Hartree-Fock; MD; molecular dynamics; MM/GBSA; molecular mechanics/generalized Born surface area; PDB; protein data bank; PME; particle mesh Ewald; MBC; metastasic bowe
Tracking binding modes of 1,2,4-trisubstituted imidazolinone P38 MAP kinase and ERK-2 inhibitors
Keywords: p38 MAP Kinase; ERK-2; Docking score; DFG-out; Hydrogen bonding; Spearman-R correlation; Ï-Cation interactions;
Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors
Keywords: B-Raf inhibitors; DFG-Out; Melanoma; Antitumor agents
Evolutionary variation and adaptation in a conserved protein kinase allosteric network: Implications for inhibitor design
Keywords: Strain-switch; EPK–ELK network; DFG-out; Imatinib; Protein kinase
Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors
Keywords: B-RafV600E; Inactive conformation; DFG-out; Structure-based design; Kinase selectivity;
Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors
Keywords: PYK2; FAK; DFG-out; Osteoporosis; Kinase inhibitor; BIRB-796;
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery
Keywords: PDK1; Selective; Tethering; Pyridinone; DFG-out; Fragment-based drug discovery
X-ray crystal structure of JNK2 complexed with the p38α inhibitor BIRB796: Insights into the rational design of DFG-out binding MAP kinase inhibitors
Keywords: JNK2; p38; BIRB796; Protein crystallography; X-ray crystal structure; DFG-out; Protein kinase; Kinase inhibitor; Structure-based drug designJNK, c-Jun N-terminal kinase; MAP, mitogen-activated protein
Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode
Keywords: cFMS; CSF-1R; Kinase; DFG-in; DFG-out; Structure-based drug design
Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α
Keywords: Kinase; Switch pocket; p38; DFG-out
Enhanced selectivity profile of pyrazole-urea based DFG-out p38α inhibitors
Keywords: Kinase inhibitor; p38; Pyrazole-urea; DFG-out
Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry
Keywords: Dynamic combinatorial chemistry; Fragment-based lead discovery; DCC; FBLD; Fragment-based; Aurora; Kinase; DFG-out; Mass-spectrometry; Site-directed; Cysteine
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes
Keywords: p38 Kinase inhibitors; MAP kinase; Biphenyl amide; Protein kinase X-ray structure; Binding mode; DFG-out; Selectivity; Kinetics